Seminars in Hematology
Volume 45 , Pages S42-S49 , April 2008

Arthropathy in Inhibitor Patients: Differences in the Joint Status

  • W. Keith Hoots

      Affiliations

    • Corresponding Author InformationAddress Correspondence to W. Keith Hoots, MD, M.D Anderson Cancer Center and University of Texas Health Science Center, Gulf States Hemophilia & Thrombophilia Center, 6655 Travis ST, Suite 400, Houston, TX 77030.

References 

  1. Queral F, Aznar JA, Haya S, Cid AR. Rehabilitation of patients with haemophilia and inhibitors. In:  Rodriguez-Merchan EC,  Lee CA editor. Inhibitors in Patients With Haemophilia. Oxford, UK: Blackwell Publishing; 2002;p. 149–160
  2. Gringeri A, Mantovani LG, Scalone L, Mannucci PM COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS Study Group. Blood. 2003;102:2358–2363
  3. Fischer K, van der Bom JG, Molho P, Negrier C, Mauser-Bunschoten EP, Roosendaal G, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: A comparison of costs and long-term outcome. Haemophilia. 2002;8:745–752
  4. Morfini M, Haya S, Tagariello G, Pollmann H, Quintana M, Siegmund B, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13:606–612
  5. Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood. 2004;103:2467–2473
  6. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) study. Blood. 2007;109:546–551
  7. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912–918
  8. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood. 1983;61:36–40
  9. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol. 1998;63(suppl):7–10
  10. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–1913
  11. Rodriguez-Merchan EC, Quintana M, De la Corte-Rodriguez H, Coya J. Radioactive synoviorthesis for the treatment of haemophilic synovitis. Haemophilia. 2007;13(suppl 3):32–37
  12. Petterson CJ, Berntorp E. Radiosynoviorthesis in patients with haemophilia and inhibitors. In:  Rodriguez-Merchan EC,  Lee CA editor. Inhibitors in Patients With Haemophilia. Oxford, UK: Blackwell Publishing; 2002;p. 130
  13. Rodriguez-Merchan EC. Synoviorthesis in hemophilia. In:  Lee CA,  Berntorp EE,  Hoots WK editor. Textbook of Hemophilia. Oxford, UK: Blackwell Publishing; 2005;p. 169–173
  14. Nuss R, Kilcoyne RF, Wiedel JD. Musculoskeletal magnetic resonance imaging. In:  Rodriguez-Merchan EC,  Lee CA editor. Inhibitors in Patients with Haemophilia. Oxford, UK: Blackwell Publishing; 2002;p. 135
  15. Wasserman J, Aday LA, Begley CE, Ahn C, Lairson DR. Measuring health state preferences for hemophilia: Development of a disease-specific utility instrument. Haemophilia. 2005;11:49–57
  16. Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost. 2004;2:1047–1054
  17. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815–825
  18. Donfield SM, Lynn HS, Lail AE, Hoots WK, Berntorp E, Gomperts ED, et al. Delays in maturation among adolescents with hemophilia and a history of inhibitors. Blood. 2007;110:3656–3661

 STATEMENT OF CONFLICT OF INTEREST: Keith Hoots has received honoraria and grant funds for research from Novo Nordisk, and has served on national and international advisory boards for Novo Nordisk.

PII: S0037-1963(08)00044-9

doi: 10.1053/j.seminhematol.2008.03.004

Seminars in Hematology
Volume 45 , Pages S42-S49 , April 2008

Article Tools

* Image Usage & Resolution